PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Cheung, Vanessa ^a   Bouralexis, Steve ^a   Gillespie, Matthew T ^a,b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; CASPASE 6; CASPASE 7; CASPASE 9; PARATHYROID HORMONE RELATED PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; APOBEC2 PROTEIN, HUMAN; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE; MUSCLE PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL STIMULATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL PROLIFERATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOBEC DEAMINASES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MUSCLE PROTEINS; PARATHYROID HORMONE-RELATED PROTEIN;

EID: 84879130104     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066343     Document Type: Article

References (49)

1. Winter MC, Coleman RE, (2009) Bisphosphonates in breast cancer: Teaching an old dog new tricks. Current Opinion in Oncology 21: 499-506.
2. Martin TJ, Moseley JM, (2000) Mechanisms in the skeletal complications of breast cancer. Endocr Relat Cancer 7: 271-284.
3. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, et al. (1987) A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237: 893-896.
4. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, et al. (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98: 1544-1549.
5. Henderson MA, Danks JA, Slavin JL, Byrnes GB, Choong PF, et al. (2006) Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res 66: 2250-2256.
6. Bouizar Z, Spyratos F, Deytieux S, de Vernejoul MC, Jullienne A, (1993) Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Research 53: 5076-5078.
7. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, et al. (1991) Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51: 3059-3061.
8. Bundred NJ, Walker RA, Ratcliffe WA, Warwick J, Morrison JM, et al. (1992) Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 28: 690-692.
9. Henderson M, Danks J, Moseley J, Slavin J, Harris T, et al. (2001) Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. J Natl Cancer Inst 93: 234-237.
10. Wiley SR, (1995) Schooley K, Smolak PJ, Din WS, Huang CP, et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682.
11. Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, et al. (1996) Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Current Biology 6: 750-752.
12. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, et al. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Journal of Biological Chemistry 271: 12687-12690.
13. Pan G, Ni J, Wei YF, Yu G, Gentz R, et al. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818.
14. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, et al. (1997) The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113.
15. Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, et al. (2010) Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 102: 506-512.
16. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, et al. (2008) Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61: 82-90.
17. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, et al. (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458.
18. Falzon M, Du P, (2000) Enhanced growth of MCF-7 breast cancer cells overexpressing parathyroid hormone-related peptide. Endocrinology 141: 1882-1892.
19. Tovar Sepulveda VA, Shen X, Falzon M, (2002) Intracrine PTHrP protects against serum starvation-induced apoptosis and regulates the cell cycle in MCF-7 breast cancer cells. Endocrinology 143: 596-606.
20. Luparello C, Romanotto R, Tipa A, Sirchia R, Olmo N, et al. (2001) Midregion parathyroid hormone-related protein inhibits growth and invasion in vitro and tumorigenesis in vivo of human breast cancer cells. J Bone Miner Res 16: 2173-2181.
21. Lam MH, Thomas RJ, Loveland KL, Schilders S, Gu M, et al. (2002) Nuclear transport of parathyroid hormone (PTH)-related protein is dependent on microtubules. Mol Endocrinol 16: 390-401.
22. Philbrick WM, Wysolmerski J, Galbraith S, Holt E, Orloff JJ, et al. (1996) Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 76: 127-173.
23. Moseley JM, Gillespie MT, (1995) Parathyroid hormone-related protein. Critical Reviews in Clinical Laboratory Sciences 32: 299-343.
24. Wysolmerski JJ, Stewart AF, (1998) The physiology of parathyroid hormone-related protein: an emerging role as a developmental factor. Annu Rev Physiol 60: 431-460.
25. Wysolmerski JJ, Philbrick WM, Dunbar ME, Lanske B, Kronenberg H, et al. (1998) Rescue of the parathyroid hormone-related protein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development. Development 125: 1285-1294.
26. Dunbar ME, Dann PR, Robinson GW, Hennighausen L, Zhang JP, et al. (1999) Parathyroid hormone-related protein signaling is necessary for sexual dimorphism during embryonic mammary development. Development 126: 3485-3493.
27. Foley J, Dann P, Hong J, Cosgrove J, Dreyer B, et al. (2001) Parathyroid hormone-related protein maintains mammary epithelial fate and triggers nipple skin differentiation during embryonic breast development. Development 128: 513-525.
28. Wysolmerski JJ, McCaughern-Carucci JF, Daifotis AG, Broadus AE, Philbrick WM, (1995) Overexpression of parathyroid hormone-related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development. Development 121: 3539-3547.
29. Ye Y, Falzon M, Seitz PK, Cooper CW, (2001) Overexpression of parathyroid hormone-related protein promotes cell growth in the rat intestinal cell line IEC-6. Regulatory Peptides 99: 169-174.
30. Okoumassoun LE, Russo C, Denizeau F, Averill-Bates D, Henderson JE, (2007) Parathyroid hormone-related protein (PTHrP) inhibits mitochondrial-dependent apoptosis through CK2. Journal of Cellular Physiology 212: 591-599.
31. Luparello C, Sirchia R, Lo Sasso B (2007) Midregion PTHrP regulates Rip1 and caspase expression in MDA-MB231 breast cancer cells. Breast Cancer Res Treat.
32. Lam MH, Briggs LJ, Hu W, Martin TJ, Gillespie MT, et al. (1999) Importin beta recognizes parathyroid hormone-related protein with high affinity and mediates its nuclear import in the absence of importin alpha. J Biol Chem 274: 7391-7398.
33. Lam MH, Henderson B, Gillespie MT, Jans DA, (2001) Dynamics of leptomycin B-sensitive nucleocytoplasmic flux of parathyroid hormone-related protein. Traffic 2: 812-819.
34. Lam MH, House CM, Tiganis T, Mitchelhill KI, Sarcevic B, et al. (1999) Phosphorylation at the cyclin-dependent kinases site (Thr85) of parathyroid hormone-related protein negatively regulates its nuclear localization. J Biol Chem 274: 18559-18566.
35. Lam MH, Hu W, Xiao CY, Gillespie MT, Jans DA, (2001) Molecular dissection of the importin beta1-recognized nuclear targeting signal of parathyroid hormone-related protein. Biochem Biophys Res Commun 282: 629-634.
36. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163.
37. Thai lM, Labrinidis A, Hay S, Liapis V, Bouralexis S, et al. (2006) Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Research 66: 5363-5370.
38. Labrinidis A, Diamond P, Martin S, Hay S, Liapis V, et al. (2009) Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res 15: 1998-2009.
39. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK, (2003) Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63: 5390-5400.
40. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, et al. (2009) TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Research and Treatment 113: 217-230.
41. Butler LM, Hay S, Findlay DM, Welldon K, Labrinidis A, et al. (2006) The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 119: 944-954.
42. Wu XX, Jin XH, Zeng Y, El Hamed AMA, Kakehi Y, (2007) Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Cancer Science 98: 1969-1976.
43. Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, et al. (2007) Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 12: 635-655.
44. Marini P, Denzinger S, Schiller D, Kauder S, Welz S, et al. (2006) Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: Enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25: 5145-5154.
45. Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, et al. (2007) Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Research 67: 6987-6994.
46. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, et al. (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of Death Receptor (DR) 5 than DR4 to apoptosis signaling. Journal of Biological Chemistry 280: 2205-2212.
47. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJS, Cohen GM, (2005) TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Research 65: 11265-11270.
48. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, et al. (2007) Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Molecular Cancer 6.
49. Henderson JE, Amizuka N, Warshawsky H, Biasotto D, Lanske BM, et al. (1995) Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol Cell Biol 15: 4064-4075.